Drugs that contain Nintedanib Esylate

1. Drug name - OFEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(1 year, 4 months from now)

US6762180 BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Oct, 2025

(3 years from now)

CN100455568C BOEHRINGER INGELHEIM 6-Position Substituted Dihydroindole Ketone, Its Preparation And Its Use As A Pharmaceutical Composition
Oct, 2020

(1 year, 11 months ago)

CN1391557A BOEHRINGER INGELHEIM 6-Position Substituted Dihydroindole Ketone, Its Preparation And Its Use As A Pharmaceutical Composition
Oct, 2020

(1 year, 11 months ago)

CN1671660A BOEHRINGER INGELHEIM 3-Z - [4 - (1 - (N - ((4-Methyl-Piperazin - -1 - Yl) - Methyl Carbonyl) - N-Methyl-Amino) - Phenylamino)--1 - Phenyl-Methylene]--6 - Methoxycarbonyl - -2 - Indolinone-Ethane Sulfonic Acid Salts And Their Use As A Pharmaceutical Composition
Jul, 2023

(9 months from now)

CN100351235C BOEHRINGER INGELHEIM 2-Ketone-Ethyl Sulfonate Of A Pharmaceutical Composition And Its Preparation
Jul, 2023

(9 months from now)

IN210415B BOEHRINGER INGELHEIM Indolinones Of General Formula I
Oct, 2020

(1 year, 11 months ago)

IN200200362P3 BOEHRINGER INGELHEIM Indolinones Substituted In 6-Position, Preparation, And Their Use As Pharmaceutical Composition
Oct, 2020

(1 year, 11 months ago)

EP1224170A1 BOEHRINGER INGELHEIM 6-Position Substituted Indoline, Production And Use Thereof As A Medicament
Oct, 2020

(1 year, 11 months ago)

EP1224170B1 BOEHRINGER INGELHEIM 6-Position Substituted Indoline, Production And Use Thereof As A Medicament
Oct, 2020

(1 year, 11 months ago)

EP1224170B9 BOEHRINGER INGELHEIM 6-Position Substituted Indoline, Production And Use Thereof As A Medicament
Oct, 2020

(1 year, 11 months ago)

EP1527047B1 BOEHRINGER INGELHEIM 3-Z- 1-(4-(N-((4-Methyl-Piperazin-1-Yl)-Methylcarbonyl)-N-Me Thyl-Amino)-Anilino)-1-Phenyl-Methylene -6-Methoxycarbonyl-2 -Indolinone-Monoethanesulphonate And The Use Thereof As A Pharmaceutical Composition
Jul, 2023

(9 months from now)

EP1527047A1 BOEHRINGER INGELHEIM 3-Z- 1-(4-(N-((4-Methyl-Piperazin-1-Yl)-Methylcarbonyl)-N-Me Thyl-Amino)-Anilino)-1-Phenyl-Methylene -6-Methoxycarbonyl-2 -Indolinone-Monoethanesulphonate And The Use Thereof As A Pharmaceutical Composition
Jul, 2023

(9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154990 BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases Dec, 2025

(3 years from now)

US10105323 BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative Jun, 2029

(6 years from now)

US9907756 BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative Jun, 2029

(6 years from now)

Treatment: Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.